Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|January 22, 2019
- Pharmaceutical Technology\'s In the Lab eNewsletter-02-06-2019
- Volume 14
- Issue 2
CRISPR Therapeutics, ProBioGen to Develop In-Vivo Delivery Technologies
Author(s)Pharmaceutical Technology Editors
The companies will embark on a multi-year research collaboration to develop in-vivo delivery modalities for CRISPR/Cas9 by leveraging ProBioGen’s existing technology and expertise.
Advertisement
On Jan. 22, 2019, CRISPR Therapeutics, a biopharmaceutical company focused on creating gene-based medicines, and ProBioGen, a German service and technology provider, announced a multi-year research collaboration to develop in-vivo delivery modalities for CRISPR/Cas9 by leveraging ProBioGen’s existing technology and expertise.
“Our CRISPR/Cas9 platform has transformative potential across a broad range of devastating, genetically-defined diseases,” said Tony Ho, MD, executive vice-president, Research and Development at CRISPR Therapeutics, in a company press release. “To ensure we deliver on this potential, we continue to seek out pioneering new technologies and capabilities in support of our programs. We look forward to working with the ProBioGen team and leveraging their expertise to enhance our research and development efforts on in-vivo delivery of CRISPR/Cas9.”
Technical and financial details of the collaboration were not disclosed. The collaboration includes a license option for CRISPR Therapeutics upon successful completion of the research goals.
Source:
Articles in this issue
over 7 years ago
Ensuring mAb Stability Through Modelingover 7 years ago
Exploring Solubility Solutionsover 7 years ago
New Reactor Flask Heating System Offers Safe Lab Optionover 7 years ago
Liquid Handlers for Automated Lab Workflowsover 7 years ago
Horizon Discovery, Rutgers Join Forces for Gene Editingover 7 years ago
Waters Launches SmartMS-Enabled LC–MS Biopharma Systemover 7 years ago
Taconic Sends Mice into Space for Therapeutic Researchover 7 years ago
Allergan to Establish R&D Presence in Cambridge, MAover 7 years ago
MedPharm Expands US Center of ExcellenceAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
Complying with International Pharmacopoeias
5